Serum paraoxonase (PON-1) activity and concentration in patients with 4th stage of chronic kidney disease

Abstract

Paraoxonase-1 (PON-1) is an enzyme with a glycoprotein structure that depends on calcium and it has cardio protective effects that protect low-density lipoprotein (LDL) and high-density lipoprotein (HDL) from oxidation and therefore retards atherosclerosis. As patients with chronic kidney disease (CKD) are at high risk of atherosclerotic, in this study, we aimed to investigate serum PON-1 activity and concentration levels among patients with 4th stage of CKD compared with the healthy control subjects, to find out the possibility of taking the PON-1 as a predictor marker of atherosclerosis in 4th stage of CKD patients. Materials and Methods: This study included 30 patients with confirmed diagnosis of 4th stage of CKD, and 30 healthy persons. Serum blood urea, creatinine, uric acid, Albumin, total cholesterol, HDL, LDL and serum triglycerides were measured. Serum level of PON-1 concentration was measured using ELISA technique, while Serum level of PON-1 activity was detected using a colorimetric method. Results: Our study showed significant increase (p<0.001) in the levels of Cholesterol, Triglyceride, LDL and VLDL in patients with 4th stage of CKD as compared to control group. Also, we found significant decreased levels of serum HDL and PON-1 in 4th stage of CKD as compared to control group (p<0.001). Conclusion: The diminution in the serum paraoxonase-1 activity and concentration may contribute to the accelerated development of atherosclerosis in patients with stage 4 of chronic kidney disease